Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same

ABSTRACT

Compounds of formula (I):  
                 
 
     wherein:  
     G represents an optionally substituted phenyl or optionally substituted heterocycle, G 1  and G 2  being N or C,  
     T 1  represents —CH 2 —CH 2 —, —CH═CH— or ═CH—CH 2 —, and T 2  is a bond, or T 1  represents —CH 2 — or ═CH— and T 2  is —CH 2 —,  
                 
 
     R 5  represents —(CH 2 )m—COOR 6 ,  
     R6 and R 6′ represent hydrogen, alkyl, optionally substituted aryl or optionally substituted arylalkyl,  
     A represents —CO—, —CH 2 —, ═CH— or —CH═ and W represents —CH—, ═C— or —C═, or A represents —CO— or —CH 2 — and W represents N,  
     X represents —CO—X 1 —, —CO—NR 6 —X 1 —, —NR 6 —CO—X 1 —, —O—X 1 —, —SO 2 —NR 6 —X 1 — or —S(O) n —X 1 —,  
     Y represents —Y 1 —, —Y 2 —Y 1 — or —Y 1 —Y 2 —Y 1 —, Y 1  being an alkylene, alkenylene or alkynylene, and Y 2  being an arylene, heteroarylene, cycloalkylene or heterocycloalkylene,  
     Z represents —Z 1 —, —Z 10 —NR 6 —, and —Z 10 —NR 6 —CO—, Z 1  being a heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, fused arylheteroaryl, fused arylheterocycloalkyl, fused heteroarylheterocycloalkyl, fused heterocycloalkylheteroaryl or fused heteroaryiheteroaryl, each of which is optionally substituted, or a group  
                 
 
     Z 2 —NR 6  or Z 2 —NT 6 —CO, Z 2  being a group Z 1 , alkyl or heteroalkyl, and Z 10  represents Z 1  or an alkyl, its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful as vitronectin receptor antagonists.

[0001] The present invention relates to new bicyclic vitronectin receptor antagonist compounds, to a process for their preparation and to pharmaceutical compositions containing them.

[0002] Integrins are a family of transmembrane glycoproteins identified initially for their dynamic characteristics of cell adhesion and cell migration and providing a mechanical bond between the extracellular matrix and other surface adhesion molecules and the cytoskeleton. Their capacity to transmit an intracellular signal directly was described subsequently. Those two properties of coupling agent and receptor are employed by cells during embryonic development and during a large number of physiological processes (Cell., 1992, 69, 11-25 ; Endocrine Reviews, 1996, 17, 207-220 ; Cell. Mol. Life Sci., 1998, 54, 514-526).

[0003] An integrin consists of two distinct chains, alpha and beta, bonded to each other in a non-covalent manner. At least sixteen alpha chains and eight beta chains have been identified, their combination allowing the creation of a vast repertoire of possibilities. Of those, only about twenty integrins have been described. The type of combination of the sub-units also dictates the repertoire of the identified extracellular ligands. The peptide sequence Arg-Gly-Asp (RGD) is often recognised by intregrins and is present in a large number of ligands (fibronectin, vitronectin, fibrinogen, collagen, . . . ), but other recognition sites have been described. An integrin can exist in a form incapable of binding its ligands and will therefore require activation by the convergence of various intracellular signals in order to be come functional (Cell., loc.cit; J. Clin. Invest., 1997, 99, 2302-2306).

[0004] If integrins are able to serve as an access route for viral, bacterial or parasitic cell infections, the deregulation of their expression or of their activation will be associated with a large number of pathologies, including, for example, cardiovascular disease, inflammatory disorders, cancer, osteoporosis, rheumatoid arthritis, psoriasis and retinopathy. Integrins take part in the development of such pathologies by acting on the adhesion and migration of cells, on the regulation of cell differentiation, survival and proliferation, and on the transmission of various intracellular signals (Ann. Rep. In Med. Chem., 1996, 31 191-200).

[0005] α_(v)β₃ integrin, one of the vitronectin receptors but binding also to fibronectin, fibrinogen and thrombospondin, has been implicated more especially in three pathological events: the migration of smooth muscle cells in neointima, during atherosclerosis and restenosis following angioplasty, to the surface of osteoclasts during bone resorption, and during phases of angiogenesis on endothelial cells (Cardiovasc. Res., 1994, 28, 1815-1820 J. Clin. Invest., 1997, 99, 2059 ; Science, 1994, 264, 569-571 ; Cell., 1994, 79, 1157-1164 ; Proc. Natl. Acad. Sci. USA, 1996, 93, 9764-9769). Tumour cells also use that integrin during their invasive phase, especially in the case of melanomas, and to ensure their survival on contact with the extracellular matrix (Proc. Natl. Acad. Sci. USA, 1992, 89, 1557-1561 and 1994, 91, 8856-8860).

[0006] α_(v)β₅ integrin, another vitronectin receptor, is also associated with angiogenesis in addition to α_(v)β₃ integrin, the two integrins taking part via two distinct routes in the induction of angiogenesis (Science, 1995, 270 1500-1502).

[0007] Finally, α_(IIB)β₃ integrin or GPIIb/IlIa is a fibrinogen receptor, and is responsible for platelet aggregation.

[0008] Blocking the interaction of the α_(v)β₃ and α_(v)β₅ integrins with their ligands is therefore likely to inhibit the adhesion, migration and survival of various cell types, effects that contribute to blocking angiogenesis, inflammation, bone resorption, restenosis, metastases and tumour growth.

[0009] The compounds of the invention have a novel structure giving them an antagonistic character towards α_(v)β₃ and α_(v)β₅ receptors of vitronectin, and rendering them selective in relation to α_(IIb)β₃ integrins. It will accordingly be possible for them to be useful in the treatment of pathologies characterised by deregulation of the expression or activation of α_(v)β₃ and/or α_(v)β₅ integrins, while avoiding the side effects in terms of platelet aggregation. In particular, it will be possible for them to be useful in the treatment of cardiovascular disease, inflammation, cancer, osteoporosis, rheumatoid arthritis, psoriasis and retinopathy.

[0010] The compounds of the invention will advantageously be useful as inhibitors of tumour growth and metastases formation in the treatment of cancer.

[0011] The present invention relates to compounds of formula (I):

[0012] wherein:

[0013] G represents a phenyl group or an aromatic or partially unsaturated heterocyclic group having 6 ring members containing 1 or 2 hetero atoms selected from nitrogen and oxygen, unsubstituted or substituted by R₁, R₂, R₃ and/or R4,

[0014] G₁ and G₂ independently represent a carbon or nitrogen atom,

[0015] -T₁- represents a group selected from —CH₂—CH₂—, —CH═CH— and ═CH—CH₂—, in which case -T₂- represents a bond, or -T₁- represents a group selected from —CH₂— and ═CH—, in which case -T₂- represents a group —CH₂—, ═CH—,

[0016] R₁, R₂, R₃ and R4 independently represent a halogen atom or an alkyl, perhaloalkyl, cyano, nitro, OR₇, NR₆R_(6′), COOR₆, CONR₆R_(6′), COR₆ or S(O)_(n)R₆ group, n being 0, 1 or 2,

[0017] R₅ represents a —(CH₂)_(m)—COOR₆ group,

[0018] R₆ and R_(6′)independently represent a hydrogen atom or an alkyl, optionally substituted aryl or optionally substituted arylalkyl group,

[0019] R₇ represents a hydrogen atom or an alkyl group,

[0020] —W— represents a —CH—, ═C— or —C═ group and -A- represents a —CO—, —CH₂—, ═CH— or —CH═ group, or —W— represents a nitrogen atom and -A- represents a —CO— or —CH₂— group,

[0021] —X— represents a group selected from —CO—X₁—, —CO—NR₆—X₁—, —NR₆—CO—X₁—, —O—X₁—, —SO₂—NR₆—X₁— and —S(O)_(n)—X₁—, wherein n is from 0 to 2 inclusive and X₁ represents an alkylene group,

[0022] —Y— represents a group selected from —Y₁—, —Y₂—Y₁— and —Y₁—Y₂—Y₁—, wherein Y₁ represents an alkylene, alkenylene or alkynylene group and Y₂ represents an arylene, heteroarylene, cycloalkylene or heterocycloalkylene group,

[0023] Z- represents a group selected from Z₁-, Z₁₀—NR₆— and Z₁₀—NR₆—CO— wherein Z₁₀ represents an alkyl group or Z₁, and Z₁ represents a group selected from Z₂-,

[0024] Z₂₀—NR₆— and Z₂₀—NR₆—CO— wherein Z₂₀ represents an alkyl or heteroalkyl group or Z₂, and Z₂ represents an optionally substituted heteroaryl group, an optionally substituted heterocycloalkyl group, an optionally substituted heteroarylalkyl group, an optionally substituted heterocycloalkylalkyl group, an optionally substituted fused arylheteroaryl group, an optionally substituted fused arylheterocycloalkyl group, an optionally substituted fused heteroarylheterocycloalkyl group, an optionally substituted fused heterocycloalkylheteroaryl group, an optionally substituted fused heteroarylheteroaryl group or a fused cycloalkylheterocycloalkyl group,

[0025] m is an integer of from 1 to 6 inclusive,

[0026] wherein:

[0027] the term “alkyl” denotes a linear or branched group having from 1 to 6 carbon atoms,

[0028] the term “heteroalkyl” denotes an alkyl group in which a carbon atom has been replaced by a hetero atom selected from nitrogen, oxygen and sulphur,

[0029] the term “alkylene” denotes a linear or branched divalent group having from 1 to 6 carbon atoms,

[0030] the term “alkenylene” denotes a linear or branched divalent group having from 2 to 6 carbon atoms and from 1 to 3 double bonds,

[0031] the term “alkynylene” denotes a linear or branched divalent group having from 2 to 6 carbon atoms and from 1 to 3 triple bonds,

[0032] the term “cycloalkyl” denotes a saturated cyclic group having from 3 to 8 carbon atoms,

[0033] the term “cycloalkylene” denotes a saturated cyclic divalent group having from 3 to 8 carbon atoms,

[0034] the term “heterocycloalkyl” denotes a saturated cyclic group having from 5 to 7 ring members and containing from 1 to 3 hetero atoms selected from nitrogen, oxygen and sulphur,

[0035] the term “aryl” denotes a phenyl group or a naphthyl group,

[0036] the term “heteroaryl” denotes an unsaturated or partially unsaturated mono- or bi-cyclic group having from 5 to 11 ring members and containing from 1 to 5 hetero atoms selected from nitrogen, oxygen and sulphur,

[0037] the expression “fused arylheteroaryl” denotes a polycyclic group formed by an aryl group and a heteroaryl group each as defined hereinabove and conjoined by means of any one of their bonds,

[0038] the expression “fused arylheterocycloalkyl” denotes a bi- or tri-cyclic group formed by an aryl group and a heterocycloalkyl group each as defined hereinabove and conjoined by means of any one of their bonds,

[0039] the expression “fused heteroarylheterocycloalkyl” denotes a bi- or tri-cyclic group formed by a heteroaryl group and a heterocycloalkyl group each as defined hereinabove and conjoined by means of any one of their bonds,

[0040] the expression “fused heterocycloalkylheteroaryl” denotes a bi- or tri-cyclic group formed by a heteroaryl group and a heterocycloalkyl group each as defined hereinabove and conjoined by means of any one of their bonds,

[0041] the expression “fused heteroarylheteroaryl” denotes a polycyclic group formed by two heteroaryl groups as defined hereinabove and conjoined by means of any one of their bonds,

[0042] the expression “fused cycloalkylheterocycloalkyl” denotes a bicyclic group formed by a cycloalkyl group and a heterocycloalkyl group each as defined hereinabove and conjoined by means of any one of their bonds,

[0043] the ending “-ene” denotes that the group in question is a divalent radical having the same meanings as the base radical,

[0044] the expression “optionally substituted” in connection with the groups heterocycloalkyl, aryl, arylalkyl, heteroaryl, fused arylheteroaryl, fused heteroaryl-heterocycloalkyl, fused heteroarylheteroaryl and fused arylheterocycloalkyl denotes that those groups are unsubstituted or substituted by one or more halogen atoms or groups alkyl, alkoxy, hydroxy, mercapto, cyano, amino (optionally substituted by one or two alkyl groups), nitro, carboxy, alkoxycarbonyl, aminocarbonyl (optionally substituted by one or two alkyl groups), wherein the heteroaryl and heterocycloalkyl groups may also be substituted by an oxo group,

[0045] to their enantiomers and diastereoisomers, and also to addition salts thereof with a pharmaceutically acceptable acid or base.

[0046] In preferred compounds of the invention, G represents a phenyl group, G₁ and G₂ each being a carbon atom.

[0047] The preferred R₅ group of the invention is the group —CH₂—COOR₆, R₆ preferably being an alkyl group or a hydrogen atom.

[0048] Preferred compounds of formula (I) are those wherein T₂ represents a bond, and even more especially those wherein T₂ represents a bond and T, represents a —CH═CH— group. Another advantageous aspect of the invention concerns compounds of formula (I) wherein T₂ represents a group

[0049] The invention relates especially to compounds of formula (I) wherein A represents a —CO—, —CH₂—, ═CH— or —CH═ group (more especially a —CH₂— or ═CH— group), and W represents a —CH—, ═C— or —C═ group (more especially a ═C— or —C═ group).

[0050] Another advantageous aspect of the invention concerns compounds of formula (I) wherein A represents a —CO— or —CH₂— group (more especially a —CO— group) and W represents a nitrogen atom.

[0051] In the compounds of formula (I), X will advantageously be selected from —CO—NR₆-X₁, —NR₆—CO—X₁ and —O—X₁, R₆ being more especially a hydrogen atom and X₁ preferably representing a methylene group.

[0052] In preferred compounds of formula (I), Y represents a Y₁ or Y₁—Y₂—Y₁ group wherein Yi is more especially an alkylene group and Y₂ advantageously represents an arylene group. More especially, Y represents a —(CH₂)₃— group.

[0053] Preferred compounds of the invention are compounds of formula (I) wherein Z represents a heteroaryl, heterocycloalkyl, fused arylheteroaryl or fused heterocycloalkylheteroaryl group or a -Z₁₀—NR₆ group, R₆ being more especially a hydrogen atom and Z₁₀ advantageously being selected from the groups heteroaryl, heterocycloalkyl, fused arylheteroaryl and fused heterocycloalkylheteroaryl. The cyclic groups thus preferred for Z advantageously contain one or two nitrogen atoms, such as, for example, the groups pyridine, aminopyridine, (dihydro)pyrrolopyridine, (dihydro)imidazole, 5,6,7,8-tetra-hydro[1,8]naphthyridine or (tetrahydro)pyrimidine.

[0054] An especially advantageous aspect of the invention concerns compounds of formula (I) wherein G represents a phenyl group, G₁ and G₂ each being a carbon atom, R₅ represents a —CH₂—COOR₆ group, R₆ being selected from a hydrogen atom and an alkyl group, T₂ represents a bond, T₁ represents a group selected from —CH═CH— and ═CH—CH₂—, A represents a —CH₂— or ═CH— group and W represents a ═C— or —C═ group. Among those, preference will be given to the compounds wherein X is selected from the groups —CO—NR₆—X₁—, —NR₆—CO—X₁— and —O—X₁—, X₁ being a methylene group, Y represents a —Y₁— or —Y₁—Y₂—Y₁ group in which Y₁ is an alkylene group and Y₂ represents an arylene group, and Z represents a heteroaryl, heterocycloalkyl, fused arylheteroaryl or fused heterocycloalkylheteroaryl group, or a Z₁₀—NR₆ group wherein Z₁₀ represents a group selected from the groups heteroaryl, heterocycloalkyl, fused arylheteroaryl and fused heterocycloalkylheteroaryl, R₆ representing a hydrogen atom.

[0055] Another especially advantageous aspect of the invention concerns compounds of formula (I) wherein G represents a phenyl group, G₁ and G₂ each being a carbon atom, R₅ represents a —CH₂—COOR₆ group, R₆ being selected from a hydrogen atom and an alkyl group, T₂ represents a bond, T₁ represents a —CH₂—CH₂— group, A represents a —CO— group and W represents a nitrogen atom. Among those, preference will be given to the compounds wherein X is selected from the groups —CO—NR₆—X₁—, —NR₆—CO—X₁— and —O—X₁—, X₁ being a methylene group, Y represents a —Y₁— or —Y₁—Y₂—Y₁ group in which Y₁ is an alkylene group and Y₂ represents an arylene group, and Z represents a heteroaryl, heterocycloalkyl, fused arylheteroaryl or fused heterocycloalkylheteroaryl group or a Z₁₀—NR₆ group wherein Z₁₀ represents a group selected from the groups heteroaryl, heterocycloalkyl, fused arylheteroaryl and fused heterocycloalkylheteroaryl, R₆ being a hydrogen atom.

[0056] Another advantageous aspect of the invention concerns compounds of formula (I) wherein G represents a phenyl group, G₁ and G₂ each being a carbon atom, R₅ represents a —CH₂—COOR₆ group, R₆ being selected from a hydrogen atom and an alkyl group, T₂ represents a group

[0057] T₁ represents a ═CH— group, A represents a —CH₂— group and W represents a —C═ group. Among those, preference will be given to the compounds wherein X is selected from the groups —CO—NR₆—X₁—, —NR₆—CO—X₁ — and —O—X₁—, X₁ being a methylene group, Y represents a —Y₁— or —Y₁—Y₂—Y₁— group in which Y₁ is an alkylene group and Y₂ represents an arylene group, and Z represents a heteroaryl, heterocycloalkyl, fused arylheteroaryl or fused heterocycloalkylheteroaryl group or a Z₁₀—NR₆ group wherein Z₁₀ represents a group selected from the groups heteroaryl, heterocycloalkyl, fused arylheteroaryl and fused heterocycloalkylheteroaryl, R₆ representing a hydrogen atom.

[0058] The preferred aryl group of the invention is the phenyl group.

[0059] Even more especially, the invention relates to the following compounds of formula (I):

[0060] [7-({[4-(2-pyridylamino)butanoyl]amino}methyl)-6,9-dihydro-5H-benzo[a]cyclo-hepten-5-yl]acetic acid hydrochloride

[0061] [7-({[5-(2-pyridylamino)pentanoyl]amino}methyl)-6,9-dihydro-5H-benzo[a]cyclo-hepten-5-yl]acetic acid hydrochloride

[0062] [7-({[4-(4,5-dihydro- IH-imidazol-2-ylamino)butanoyl]amino}methyl)-6,9-dihydro-5H-benzo[a]cyclohepten-5-yl]acetic acid hydrochloride

[0063] [7-({[4-(1,4,5 ,6-tetrahydro-2-pyrimidinylamino)butanoyl]amino } methyl)-6,9-dihydro-5H-benzo[a]cyclohepten-5-yl]acetic acid hydrochloride

[0064] [7-({[4-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)butanoyl]amino}methyl)-6,9-dihydro-5H-benzo[a]cyclohepten-5-yl]acetic acid hydrochloride

[0065] [7-(2-oxo-2-{3-(2-pyridylamino)propyl]amino}ethyl)-5H-benzo[a]cyclohepten-5-yl]acetic acid

[0066] [7-({[4-(2-pyridylamino)butanoyl]amino}methyl)-5H-benzo[a]cyclohepten-5-yl]acetic acid

[0067] [7-({[4-(1 H-benzimidazol-2-ylamino)butanoyl]amino}methyl)-5H-benzo[a]cyclo-hepten-5-yl]acetic acid

[0068] [7-({[4-(1 4-benzimidazol-2-ylamino)butanoyl]amino}methyl)-6,9-dihydro-5H-benzo[a]cyclohepten-5-yl]acetic acid

[0069] Amongst the pharmaceutically acceptable acids there may be mentioned hydrochloric, hydrobromic, sulphuric, phosphonic, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric, ascorbic, methanesulphonic, camphoric acid etc . . .

[0070] Amongst the pharmaceutically acceptable bases there may be mentioned sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine, etc . . .

[0071] The present invention relates also to a process for the preparation of the compounds of formula (I).

[0072] The process for the preparation of the compounds of formula (I) is characterised in that:

[0073] when, in the compounds of formula (I) it is desired to obtain, A represents a —CO—, —CH₂—, ═CH— or —CH═ group and W represents a —CH—, ═C— or —C═ group, the starting material used is a compound of formula (II/a):

[0074] wherein G, G₁, G₂, T₁, T₂ and R₅ are as defined for formula (I), W and A are as defined hereinabove, and R represents a CHO, CN or AlkOOC—CH═ group,

[0075] which, when R represents a formyl group, is subjected to a Wittig or Homer Emons reaction so as to homologise the chain carrying the aldehyde function, by using the appropriate reagent, to yield a compound of formula (III/a):

[0076] wherein G, G₁, G₂, T₁, T₂, R₅, A and W are as defined hereinabove, X′₁ represents an alkylene or alkenylene group having from two to six carbon atoms and R_(a) represents a cyano, formyl or alkoxycarbonyl group according to the reagent chosen,

[0077] which compound (III/a), with the compounds of formula (III/b):

[0078] a particular case of the compounds of formula (II/a) wherein G, G₁ , G₂, T₁, T₂, R₅, W and A are as defined hereinabove and Alk represents an alkyl group, the broken lines indicating the optional presence of a double bond,

[0079] constitute the entirety of the compounds of formula (III-I):

[0080] wherein G, G₁, G₂, T₁, T₂, W, A and R_(a) are as defined hereinabove and X₁ is as defined for formula (I),

[0081] or, when, in the compounds of formula (I) it is desired to obtain, A represents a —CO— or —CH₂— group and W represents a nitrogen atom, the starting material used is a compound of formula (II/b):

[0082] wherein G, G₁, G₂, T₁, T₂ and R₅ are as defined for formula (I) and A is as defined hereinabove,

[0083] which is condensed, in basic medium, with a compound of formula R_(b)—X₁—Hal, wherein X₁ is as defined for formula (I), Hal represents a halogen atom and R_(b) represents an alkoxycarbonyl or hydroxy group, the latter groups optionally being protected, to yield a compound of formula (111-2):

[0084] wherein G, G₁, G₂, T₁, T₂, R₅, R_(b), A and X₁ are as defined hereinabove, the compounds (III-1) and (III-2) constituting the totality of the compounds of formula (III):

[0085] wherein G, G₁, G₂, T₁, T₂, R₅, W, A and X₁ are as defined for formula (I) and R_(ab) has the same meanings as the groups R_(a) and R_(b) combined, the R_(ab) group of which compound (III) is either reduced in alcohol, or deprotected when it represents a masked hydroxy group, to yield a compound of formula (IV):

[0086] wherein G, G₁, G₂, T₁, T₂, R₅, W, A and X₁ are as defined for formula (I),

[0087] which is subjected to a halogenation reaction to yield a compound of formula (V):

[0088] wherein G, G₁, G₂, T₁, T₂, R₅, A, W and X₁ are as defined hereinabove and Hal represents a halogen atom,

[0089] which is treated, in basic medium, with a compound of formula Z—Y—OH wherein Z and Y are as defined for formula (I), to yield a compound of formula (I/a):

[0090] a particular case of the compounds of formula (I) wherein G, G₁, G2, T₁, T₂, R₅, X₁, W, A, Y and Z are as defined for formula (I),

[0091] or which is treated, in basic medium, with a compound of formula Z—Y—SH wherein Z and Y are as defined for formula (I), to yield a compound of formula (I/b):

[0092] a particular case of the compounds of formula (I) wherein G, G₁ , G₂, T₁, T₂, R₅, X₁, W, A, Y and Z are as defined for formula (I),

[0093] the sulphur atom of which may be oxidised to yield a compound of formula (I/c):

[0094] a particular case of the compounds of formula (I) wherein G, G₁, G₂, T₁, T₂, R₅, X₁, W, A, Y and Z are as defined for formula (I) and n′ represents an integer 1 or 2, or,

[0095] which compound of formula (V), subjected to the action of a cyclic imide in basic medium, followed by treatment with hydrazine in alcoholic medium, yields an amine of formula (VI):

[0096] wherein G, G₁, G₂, T₁, T₂, R₅, X₁, A and W are as defined hereinabove, it being possible furthermore for the compound of formula (VI) to be obtained directly, when X₁ represents a CH₂ group, by reduction of a compound of formula (II/a) wherein R represents a CN group,

[0097] which compound of formula (VI) is treated with a compound of formula (VII):

[0098] wherein Z and Y are as defined for formula (I),

[0099] to yield a compound of formula (I/d):

[0100] a particular case of the compounds of formula (I) wherein G, G₁, G₂, T₁, T₂, R₅, X₁, A, W, Z and Y are as defined for formula (I),

[0101] or is treated with a sulphonyl chloride of formula Z—Y—SO₂—C1, wherein Z and Y are as defined for formula (I), to yield a compound of formula (I/e):

[0102] a particular case of the compounds of formula (I) wherein G, G₁, G₂, T₁, T₂, R₅, X₁, A, W, Z and Y are as defined hereinabove for formula (I), or the R_(ab) group of which compound of formula (III) is converted into the corresponding acid to yield a compound of formula (VIII):

[0103] wherein G, G₁, G₂, T₁, T₂, R₅, W, A and X₁ are as defined for formula (I),

[0104] which is subjected either to the action of an amine of formula Z—Y—NH₂ or the corresponding salt to yield a compound of formula (I/f):

[0105] a particular case of the compounds of formula (I) wherein G, G₁, G₂, T₁, T₂, R₅, A, W, X₁, Z and Y are as defined for formula (I),

[0106] or to the action of an amine of formula:

[0107] to yield a compound of formula (IX):

[0108] wherein G, G₁, G₂, T₁, T₂, R₅, A, W and X₁ are as defined hereinabove, which is then subjected to the action of a lithium compound of formula Z—Y—Li, wherein Y and Z are as defined for formula (I), to yield a compound of formula (I/g):

[0109] a particular case of the compounds of formula (I) wherein G, G₁, G₂, T₁, T₂, X₁, W, A, Z and Y are as defined for formula (I),

[0110] which compounds (I/a) to (I/g), which constitute the totality of the compounds of formula (I),

[0111] may, if desired, be purified according to a conventional purification technique,

[0112] are optionally separated into their stereoisomers according to a conventional separation technique,

[0113] are, if desired, converted into their addition salts with a pharmaceutically acceptable acid or base.

[0114] A variant of the process described above when, in the compounds of formula (I) it is desired to obtain, A represents a CO group and W represents a nitrogen atom, comprises using as starting material a compound of formula (II/b) as defined hereinabove, which is condensed in basic medium with a compound of formula Z—Y—X), wherein Z, Y and X are as defined for formula (I) and ( represents a leaving group (for example a halogen atom or a tosyl group), to yield, directly, a compound of formula (I/h):

[0115] a particular case of the compounds of formula (I) wherein G, G₁, G₂, T₁, T₂, R₅, X, Y and Z are as defined for formula (I).

[0116] Another advantageous variant of the process described hereinabove when, in the compounds of formula (I) it is desired to obtain, Z represents a Z₁₀NR₆ group, comprises using as starting material a compound of formula (X):

[0117] wherein Y, X, W, T₁, G, G₁, G₂, T₂, A, R₅ and R₆ are as defined for formula (I), which is condensed, in basic medium or in the presence of a catalyst, with a compound of formula (X₁):

X₁₀_{circle over (P′)}  (XI)

[0118] wherein Z₁₀ is as defined for formula (I) and {circle over (P′)} represents a leaving group (for example a halogen atom, a tosyl group or a methylthio or thioxo group)

[0119] to yield a compound of formula (I/i), a particular case of the compounds of formula (I):

[0120] wherein Z₁₀ R₆ Y, X, W, A, T₁, T₂, G₁, G₂, R₅ and G are as defined hereinabove,

[0121] which may, if desired, be purified according to a conventional purification technique,

[0122] which is optionally separated into its stereoisomers according to a conventional separation technique,

[0123] which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base.

[0124] The starting materials used are either known or are prepared according to known procedures.

[0125] In particular, the compounds of formula (II/a) wherein G, G₁ and G₂ together form a phenyl group may be prepared in the following manner, starting from 5,6,8,9-tetrahydro-7H-benzocyclohepten-7-one (2):

[0126] The compound (2) may be subjected to a dihalogenation reaction in the position aX to the carbonyl to yield, after an elimination reaction in basic medium, the unsaturated compound (3):

[0127] which is treated in the presence of mercury salts with a ketene acetal of formula (4):

[0128] wherein R₆ is as defined for formula (I),

[0129] to yield a compound of formula (5):

[0130] wherein R₆ is as defined hereinabove, which is treated:

[0131] either with chloromethyltrimethylsilane in basic medium to yield, after rearrangement in the presence of silica, a compound of formula (6-II/a):

[0132] a particular case of the compounds of formula (II/a) wherein R₆ is as defined for formula (I),

[0133] or with methyllithium to yield, after dehydration, a compound (7):

[0134] wherein R₆ is as defined hereinabove,

[0135] the methyl of which is oxidised with an appropriate reagent to yield the corresponding aldehyde (8-II/a):

[0136] a particular case of the compounds of formula (II/a) wherein R₆ is as defined for formula (I).

[0137] The ketone (2) as defined hereinabove may also be treated with trimethylsilyl chloride in strong basic medium to yield, after oxidation, the unsaturated compound (9):

[0138] which is condensed in basic medium with a compound of formula Hal-(CH₂)m—COOR6, wherein m and R₆ are as defined for formula (I) and Hal represents a halogen atom, to yield a compound (10):

[0139] wherein R₅ is as defined for formula (I),

[0140] which compound (10) is subjected to the action of carbon monoxide in the presence of a base in a THF/water medium to yield a compound (11-II/a):

[0141] a particular case of the compounds of formula (II/a) wherein R₅ is as defined for formula (I).

[0142] The symmetric ketone (2) can also be converted into the dissymmetric ketone (12):

[0143] in accordance with the procedure described in J.O.C., 1980, 45 3028,

[0144] which compound (12) may be subjected to a dihalogenation reaction to yield, after an elimination reaction, a compound of formula (13):

[0145] wherein Hal represents a halogen atom,

[0146] which is treated:

[0147] either with a ketene acetal of formula (4) as defined hereinabove, in the presence of mercury salts, to yield a compound of formula (14):

[0148] wherein R₆ is as defined for formula (I) and Hal represents a halogen atom,

[0149] which is subjected to a Wittig-type reaction using (methoxymethyl)triphenyl-phosphonium chloride to yield, after treatment in acidic medium, a compound of 

We claim:
 33. A compound selected from those of formula (I):

wherein: G represents a phenyl or an aromatic or partially unsaturated heterocyclic group having 6 ring members containing 1 or 2 hetero atoms selected from nitrogen and oxygen, unsubstituted or substituted by R₁, R₂, R₃ and/or R₄, G₁ and G₂ independently represent a carbon or nitrogen, -T₁- represents a group selected from —CH₂—CH₂—, —CH═CH— and ═CH—CH₂—, in which case -T₂- represents a bond, or -T₁- represents a group selected from —CH₂— and ═CG—, in which case -T₂- represents a group —CH₂—, ═CG—,

R₁, R₂, R₃ and R₄ independently represent halogen, alkyl, perhaloalkyl, cyano, nitro, OR₇, NR₆R_(6′), COOR₆, CONR₆R_(6′), COR₆ or S(O)_(n)R₆, wherein n is 0, 1 or 2, R₅ represents a —(CH₂)_(m)—COOR₆, R₆ and R_(6′) independently represent hydrogen, alkyl, optionally substituted aryl, or optionally substituted arylalkyl, R₇ represents a hydrogen or an alkyl, —W— represents —CG—, ═C— or —C═ and -A- represents —CO—, —CH₂—, ═CH— or —CH═, or —W— represents nitrogen and —A— represents —CO— or —CH₂—, —X— represents a group selected from —CO—X₁—, —CO—NR₆—X₁—, —NR₆—CO—X₁—, —O—X₁—, —SO₂—NR₆—X₁— and —S(O)_(n)—X₁—, wherein n is from 0 to 2 inclusive and X₁ represents an alkylene, —Y— represents a group selected from —Y₁—, —Y₂—Y₁—, and —Y₁—Y₂—Y₁—, wherein Y, represents alkylene, alkenylene, or alkynylene, and Y₂ represents arylene, heteroarylene, cycloalkylene, or heterocycloalkylene, Z- represents a group selected from Z₁-, Z₁₀—NR₆— and Z₁₀—NR₆—CO— wherein Z₁₀ represents an alkyl or Z₁, and Z₁ represents a group selected from Z₂-,

Z₂₀—NR₆— and Z₂₀—NR₆—CO—, wherein Z₂₀ represents alkyl, heteroalkyl, NR₆ or Z₂, and Z₂ represents an optionally substituted heteroaryl, an optionally substituted heterocycloalkyl, an optionally substituted heteroarylalkyl, an optionally substituted heterocycloalkylalkyl, an optionally substituted fused arylheteroaryl, an optionally substituted fused arylheterocycloalkyl, an optionally substituted fused heteroarylheterocycloalkyl, an optionally substituted fused heterocycloalkylheteroaryl, an optionally substituted fused heteroarylheteroaryl or a fused cycloalkylheterocycloalkyl, m is an integer of from 1 to 6 inclusive, wherein: “alkyl” is a linear or branched, 1 to 6 carbon alkyl group, “heteroalkyl” is an alkyl in which a carbon atom has been replaced by a hetero atom selected from nitrogen, oxygen and sulphur, “alkylene” is a linear or branched divalent 1 to 6 carbon group, “alkenylene” is a linear or branched divalent 2 to 6 carbon group with I to 3 double bonds, “alkynylene” is a linear or branched divalent 2 to 6 carbon group with 1 to 3 triple bonds, “cycloalkyl” is a saturated 3 to 8 carbon cyclic group, “cycloalkylene” is a saturated 3 to 8 carbon cyclic divalent group, “heterocycloalkyl” is a saturated cyclic 5 to 7 ring membered group with I to 3 hetero atoms selected from nitrogen, oxygen and sulphur, “aryl” is a phenyl or naphthyl, “heteroaryl” is an unsaturated or partially unsaturated mono- or bi-cyclic 5 to 11 membered group with 1 to 5 hetero atoms selected from nitrogen, oxygen and sulphur, “fused arylheteroaryl” is a polycyclic group formed by an aryl and a heteroaryl, each as defined hereinabove, and conjoined by means of any one of their bonds, “fused arylheterocycloalkyl” is a bi- or tri-cyclic group formed by an aryl and a heterocycloalkyl, each as defined hereinabove, and conjoined by means of any one of their bonds, “fused heteroarylheterocycloalkyl” is a bi- or tri-cyclic group formed by a heteroaryl and a heterocycloalkyl, each as defined hereinabove, and conjoined by means of any one of their bonds, “fused heterocycloalkylheteroaryl” is a bi- or tri-cyclic group formed by a heteroaryl and a heterocycloalkyl, each as defined hereinabove, and conjoined by means of any one of their bonds, “fused heteroarylheteroaryl” is a polycyclic group formed by two heteroaryl groups, as defined hereinabove, and conjoined by means of any one of their bonds, “fused cycloalkylheterocycloalkyl” is a bicyclic group formed by a cycloalkyl and a heterocycloalkyl, each as defined hereinabove, and conjoined by means of any one of their bonds, the ending “-ene” is that the group in question is a divalent radical having the same meanings as the base radical, the expression “optionally substituted” in connection with the groups heterocycloalkyl, aryl, arylalkyl, heteroaryl, fused arylheteroaryl, fused heteroarylheterocycloalkyl, fused heteroarylheteroaryl and fused arylheterocycloalkyl is that those groups are unsubstituted or substituted by one or more atoms or groups selected from alkyl, alkoxy, hydroxy, mercapto, cyano, amino (optionally substituted by one or two alkyl), nitro, carboxy, alkoxycarbonyl, aminocarbonyl (optionally substituted by one or two alkyl), wherein the heteroaryl and heterocycloalkyl groups may also be substituted by an oxo, its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
 34. A compound of claim 33, wherein G represents a phenyl, and G₁ and G₂ each represent a carbon.
 35. A compound of claim 33, wherein R₅ represents a —CH₂—COOR₆ group.
 36. A compound of claim 33, wherein T₂ represents a bond.
 37. A compound of claim 33, wherein T₂ represents a group


38. A compound of claim 33, wherein A represents —CO—, —CH₂—, ═CH— or —CH═ and W represents —CG—, ═C— or —C═.
 39. A compound of claim 33, wherein A represents —CO— or —CH₂— and W represents nitrogen.
 40. A compound of claim 33, wherein X is selected from —CO—NR₆—X₁, —NR₆—CO—X₁ and —O—X₁.
 41. A compound of claim 33, wherein Y represents Y, or the group Y₁—Y₂—Y₁.
 42. A compound of claim 33, wherein Z represents a heteroaryl, heterocycloalkyl, fused arylheteroaryl or fused heterocycloalkylheteroaryl.
 43. A compound of claim 33, wherein Z represents Z₁₀—NR₆.
 44. A compound of claim 33, wherein G represents phenyl, G₁ and G₂ each represent a carbon, R₅ represents a —CH₂—COOR₆, R₆ is selected from hydrogen and alkyl, T₂ represents a bond, T₁ represents a group selected from —CH═CH— and ═CH—CH₂—, A represents —CO—, —CH₂— or —CH═ and W represents a —CH— or —C═.
 45. A compound of claim 33, wherein X is selected from —CO—NR₆—X₁—, —NR₆—CO—X₁— and —O—X₁—, X₁ is methylene, Y represents —Y₁— or the group —Y₁—Y₂—Y₁ in which Y₁ is alkylene and Y₂ represents arylene, and Z represents heteroaryl, heterocycloalkyl, fused arylheteroaryl or fused heterocycloalkylheteroaryl or Z₁₀—NR₆ wherein Z₁₀ represents a group selected from heteroaryl, heterocycloalkyl, fused arylheteroaryl and fused heterocycloalkylheteroaryl, and R₆ is hydrogen.
 46. A compound of claim 33, wherein G represents phenyl, G₁ and G₂ each represent a carbon, R₅ represents —CH₂—COOR₆, R₆ is selected from hydrogen and alkyl, T₂ is a bond, T₁ is —CH₂—CH₂—, A is —CO— and W is nitrogen.
 47. A compound of claim 33, wherein X is selected from —CO—NR₆—X₁—, —NR₆—CO—X₁—and —O—X₁—, X₁ is methylene, Y represents —Y₁— or thr group —Y₁—Y₂—Y₁ in which Y₁ is alkylene and Y₂ is arylene, and Z represents heteroaryl, heterocycloalkyl, fused arylheteroaryl or fused heterocycloalkylheteroaryl or Z₁₀—NR6, wherein Zl₀ represents a group selected from heteroaryl, heterocycloalkyl, fused arylheteroaryl and fused heterocycloalkylheteroaryl, and R₆ is hydrogen.
 48. A compound of claim 33, wherein G represents phenyl, G₁ and G₂ each represent a carbon, R₅ represents —CH₂—COOR₆, R₆ is selected from hydrogen and alkyl, T₂ is a group

T₁ is ═CG—, A is —CH₂— and W is —C═.
 49. A compound of claim 33, wherein X is selected from —CO—NR₆—CO—X₁—, —NR₆—CO—X₁— and —O—X₁—, X₁ is methylene, Y represents —Y₁— or the group —Y₁—Y₂—Y₁ in which Y₁ is alkylene and Y₂ represents arylene, and Z represents heteroaryl, heterocycloalkyl, fused arylheteroaryl or fused heterocycloalkylheteroaryl or Z₁₀—NR₆, wherein Z₁₀ represents a group selected from heteroaryl, heterocycloalkyl, fused arylheteroaryl and fused heterocycloalkylheteroaryl, and R₆ is hydrogen.
 50. A compound of claim 33, which is [7-({[4-(2-pyridylamino)butanoyl]amino}methyl)-6,9-dihydro-5H-benzo[a]cyclohepten-5-yl]acetic acid.
 51. A compound of claim 33, which is [7-({[5-(2-pyridylamino)pentanoyl]amino}methyl)-6,9-dihydro-5H-benzo[a]cyclohepten-5-yl]acetic acid hydrochloride.
 52. A compound of claim 33, which is [7-(2-oxo-2-{[3-(2-pyridylamino)propyl]amino}ethyl)-5H-benzo[a]cyclohepten-5-yl]acetic acid.
 53. A compound of claim 33, which is [7-({[4-(4,5-dihydro-IH-imidazol-2-ylamino)-butanoyl]amino}methyl)-6,9-dihydro-5H-benzo[a]cyclohepten-5-yl]acetic acid hydro-chloride.
 54. A compound of claim 33, which is [7-({[4-(2-pyridylamino)butanoyl]amino}methyl)-5H-benzo[a]cyclohepten-5-yl]acetic acid.
 55. A compound of claim 33, which is [7-({[4-(1H-benzimidazol-2-ylamino)butanoyl]-amino}methyl)-5H-benzo[a]cyclohepten-5-yl]acetic acid.
 56. A compound of claim 33, which is [7-({[4-(1H-benzimidazol-2-ylamino)butanoyl]-amino}methyl)-6,9-dihydro-5H-benzo[a]cyclohepten-5-yl]acetic acid.
 57. A compound of claim 33, which is [7-({[4-(1,4,5,6-tetrahydro-2-pyrimidinylamino)-butanoyl]amino}methyl)-6,9-dihydro-5H-benzo[a]cyclohepten-5-yl]acetic acid hydrochloride.
 58. A compound of claim 33, which is [7-({[4-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)-butanoyl]amino}methyl)-6,9-dihydro-5H-benzo[a]cyclohepten-5-yl]acetic acid hydrochloride.
 59. A pharmaceutical composition comprising as active principle an effective amount of at least one compound of claim 33, alone or together with one or more pharmaceutically acceptable, excipients or carriers.
 60. A method for treating animal or living body afflicted with a condition treatable by a vitronectin receptor antagonist, such condition selected from cardiovascular disease, inflammatory disorders, cancer, osteoporosis, rheumatoid arthritis, psoriasis and retinopathy comprising the step of administering to the living body an amount of a compound of claim 33 which is effective for alleviation of the condition.
 61. A method for treating an animal or living body afflicted with a condition treatable by an inhibitor of tumour growth and of metastases formation, such as cancer, comprising the step of administering to the living body an amount of compound of claim 33 which is effective for alleviation of said condition. 